Hannah joined the Benesch group for her Part II in September 2024, where she used biophysical techniques to characterise anti-EGFR nanobodies to develop a single cell assay, jointly supervised by the Aarts group. For her DPhil, Hannah is focusing on using mass spectrometry to better understand clinical biomarkers, including Epidermal Growth Factor Receptor and Osteopontin.
This is some filler text to fill the gap with This is some filler text to fill the gap with This is some filler text to fill the gap with This is some fillerThis is some filler text to fill the gap with This is some filler text to fill the gap with This is some filler text to fill the gap with This is some filler